Hematological Disease Clinical Trial
— AuToMIOfficial title:
Artificial Intelligence Algorithms to Automate the Total Marrow (Lymph-node) Irradiation by VMAT Optimization Using WB-CT/MRI and Synthetic WB-CT - The AuToMI Project
NCT number | NCT04976205 |
Other study ID # | 2928 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 15, 2021 |
Est. completion date | September 2024 |
Total Body Irradiation (TBI) was shown to help in providing immunosuppression that facilitates the donor transplant acceptance. Randomized trials demonstrated that conditioning regimens to bone marrow transplantation (BMT) including TBI have produced better survival rates than chemo-only regimens. The TBI target is represented by the whole BM, and eventually the whole lymphatic system, liver, spleen. The increased life expectancy revealed the occurrence of important toxicities because of full doses received by organs at risk (OARs) and this limited the use of TBI. Many groups have explored the possibility of sophisticated techniques for reducing the dose to healthy tissues while increasing the dose to the BM. These newer approaches aim to generate total marrow (lymph-node) irradiation (TMI/TMLI), sparing as much as possible non-skeletal and non-lymphoid structures. Actually, the time required to optimize a TMI/TMLI plan is 10 days. Therefore, the simulation Computed Tomography (CT) is performed many days before the BMT. Furthermore, the lymph-nodes are defined only on CT images.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Written, signed informed consent - Adult patients aged =18 years - Diagnosis of Hematological disease - Eligibility for allogeneic stem cell transplantation as center guidelines - TMI/TLI as part of the conditioning regimen Exclusion Criteria: - Conditioning regimen including only chemotherapeutic agents |
Country | Name | City | State |
---|---|---|---|
Italy | IRCCS Humanitas Research Center | Rozzano | Milano |
Lead Sponsor | Collaborator |
---|---|
Istituto Clinico Humanitas |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction of Lymph nodes target volume thanks to WB-MRI | The PTV_LN volumes generated on the Simulation WB-MRI and on the Simulation WB-CT will be compared. | 3 years | |
Secondary | Doses calcuated on CT performed at day -3 (4) to the BMT | To evaluate the dosimetric changes that occurs in the days between the simulation and the delivery.
The RT plan is defined on a simulation CT perfomed at -15 days. A second CT is performed at day -3 (4) to the BMT. The RT plan is recalculated on the second CT. The PTV volume receiving 95% of doses will be recorded. |
3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02660281 -
URMC Related Haplo-identical Donor BMT
|
Phase 1 | |
Completed |
NCT03004261 -
CMV-CTL for the Treatment of CMV Infection After HSCT
|
Phase 4 | |
Recruiting |
NCT01684189 -
Registry of Febrile Neutropenia and Invasive Fungal Infections
|
N/A | |
Completed |
NCT02447237 -
Randomized Trial:the Effect of Liquid Food on the Intake of Energy and Protein in Malignant Hematologic Patients
|
N/A | |
Not yet recruiting |
NCT06143098 -
Some Hematological Profile in Children With Chronic Kidney Disease
|
||
Not yet recruiting |
NCT06050798 -
Hematological Disorder in Patients With Angiodysplasia
|
||
Active, not recruiting |
NCT02158858 -
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT02456818 -
Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards
|
N/A | |
Recruiting |
NCT05727917 -
Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT03355742 -
XIENCE 28 Global Study
|
N/A | |
Recruiting |
NCT00883961 -
Exercise Following Autologous Peripheral Blood Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT00820508 -
Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies
|
Phase 1 | |
Terminated |
NCT01359254 -
Cord Blood Transplantation for Patients With Cancer
|
Phase 2 |